Status:
TERMINATED
One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease
Lead Sponsor:
Bausch Health Americas, Inc.
Collaborating Sponsors:
Salix Pharmaceuticals, Inc. a division of Bausch Health US, LLC
Conditions:
Crohn's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The primary objective is to determine the efficacy of rifaximin DR also referred to as Extended Intestinal Release (EIR) tablets vs. placebo for the induction of clinical remission and endoscopic resp...
Detailed Description
RECD3125 is a double-blind, placebo-controlled, parallel-group, multicenter, multiregional, 52-week study to assess the efficacy and safety of rifaximin DR tablets for the induction of clinical remiss...
Eligibility Criteria
Inclusion
- Major
- Moderate, non-fistulizing Crohn's disease in the ileum and/or colon prior to randomization; and a SES-CD score of ≥7 (confirmed by centralized endoscopy reading).
- During the screening period, the participant will need to have certain average daily scores for abdominal pain and average number of liquid/very soft stools.
- Major
Exclusion
- Pregnant or lactating females. Females of childbearing (reproductive) potential must have a negative serum pregnancy test at screening and agree to use a highly effective method(s) of contraception throughout their participation in the study. Diagnosis of ulcerative or indeterminate colitis.
- Diagnosis of Celiac Disease.
- Bowel surgery within 12 weeks prior to screening and/or has surgery planned or deemed likely for Crohn's disease during the study period.
- Presence of an ileostomy or colostomy.
- Known fixed symptomatic stenosis/stricture of the small or large bowel.
- Had more than one segmental colonic resection.
- Had more than 3 small bowel resections or symptoms associated with short bowel syndrome.
- Current evidence of peritonitis.
- History or evidence of colonic mucosal dysplasia.
- History or evidence of adenomatous colonic polyps that have not been removed.
- Unwilling to be tapered off corticosteroids by Week 8 or the participant is known by the Investigator to be steroid-dependent.
- Has used a biologic within 12 weeks of randomization.
- Used cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, or similar drugs within 8 weeks prior to randomization.
- Had rectal administration of 5-aminosalicylic acid (5-ASA) or corticosteroid enemas/foams/ suppositories within 2 weeks prior to screening visit.
Key Trial Info
Start Date :
August 21 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 16 2017
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT02240121
Start Date
August 21 2014
End Date
August 16 2017
Last Update
September 10 2019
Active Locations (72)
Enter a location and click search to find clinical trials sorted by distance.
1
Scottsdale, Arizona, United States, 85260
2
Tucson, Arizona, United States, 85712
3
Tucson, Arizona, United States, 85724
4
Little Rock, Arkansas, United States, 72205